Genmab/Medarex files clinical trial application in Europe  

Genmab/Medarex files CTA for HuMax-Inflam in the treatment of an autoimmune disease

Biotech companies Genmab and Medarex have filed a clinical trial application (CTA) in Europe for HuMax-Inflam, otherwise known as MDX-018, for use in the treatment of a so far un-named autoimmune disease. A CTA filing is the equivalent of an investigational new drug (IND) application in the US and is a request to the regulatory authorities in Europe to seek approval to conduct a clinical study in patients. Genmab and Medarex plan to share all development costs and world-wide rights to HuMax-Inflam, except for Asia, which is held by Medarex. The news is reported in Berlingske Tidende today.


An offshoot of the US company Medarex, Genmab A/S creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, rheumatoid arthritis and other inflammatory conditions, and plans to assemble a broad portfolio of new therapeutic products arising from research into the human genome. Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, The Netherlands and Princeton, New Jersey, US.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×